These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 36737259)

  • 21. Variation in treatment associated with life expectancy in a population-based cohort of men with early-stage prostate cancer.
    Daskivich TJ; Lai J; Dick AW; Setodji CM; Hanley JM; Litwin MS; Saigal C;
    Cancer; 2014 Dec; 120(23):3642-50. PubMed ID: 25042117
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A decision support model for cost-effectiveness of radical prostatectomy in localized prostate cancer.
    Lyth J; Andersson SO; Andrén O; Johansson JE; Carlsson P; Shahsavar N
    Scand J Urol Nephrol; 2012 Feb; 46(1):19-25. PubMed ID: 21905981
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-effectiveness Analysis of Active Surveillance Strategies for Men with Low-risk Prostate Cancer.
    Sathianathen NJ; Konety BR; Alarid-Escudero F; Lawrentschuk N; Bolton DM; Kuntz KM
    Eur Urol; 2019 Jun; 75(6):910-917. PubMed ID: 30425010
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Observation versus initial treatment for men with localized, low-risk prostate cancer: a cost-effectiveness analysis.
    Hayes JH; Ollendorf DA; Pearson SD; Barry MJ; Kantoff PW; Lee PA; McMahon PM
    Ann Intern Med; 2013 Jun; 158(12):853-60. PubMed ID: 23778902
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-Effectiveness of Active Surveillance, Radical Prostatectomy and External Beam Radiotherapy for Localized Prostate Cancer: An Analysis of the ProtecT Trial.
    Sharma V; Wymer KM; Borah BJ; Barocas DA; Thompson RH; Karnes RJ; Boorjian SA
    J Urol; 2019 Nov; 202(5):964-972. PubMed ID: 31112105
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Morbidity and costs of salvage vs. primary radical prostatectomy in older men.
    Prasad SM; Gu X; Kowalczyk KJ; Lipsitz SR; Nguyen PL; Hu JC
    Urol Oncol; 2013 Nov; 31(8):1477-82. PubMed ID: 22575240
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost effectiveness of risk-prediction tools in selecting patients for immediate post-prostatectomy treatment.
    Zubek VB; Konski A
    Mol Diagn Ther; 2009; 13(1):31-47. PubMed ID: 19351214
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of Prostate Cancer Severity on Functional Outcomes After Localized Treatment: Comparative Effectiveness Analysis of Surgery and Radiation Study Results.
    Tyson MD; Koyama T; Lee D; Hoffman KE; Resnick MJ; Wu XC; Cooperberg MR; Goodman M; Greenfield S; Hamilton AS; Hashibe M; Paddock LE; Stroup A; Chen V; Conwill R; McCollum D; Penson DF; Barocas DA
    Eur Urol; 2018 Jul; 74(1):26-33. PubMed ID: 29501451
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The impact of age at the time of radiotherapy for localized prostate cancer on the development of second primary malignancies.
    Krasnow RE; Rodríguez D; Nagle RT; Mossanen M; Kibel AS; Chang SL
    Urol Oncol; 2018 Nov; 36(11):500.e11-500.e19. PubMed ID: 30249519
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A framework to evaluate the cost-effectiveness of the NADiA ProsVue slope to guide adjuvant radiotherapy among men with high-risk characteristics following prostatectomy for prostate cancer.
    Reed SD; Stewart SB; Scales CD; Moul JW
    Value Health; 2014 Jul; 17(5):545-54. PubMed ID: 25128047
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Radical prostatectomy versus deferred treatment for localised prostate cancer.
    Vernooij RW; Lancee M; Cleves A; Dahm P; Bangma CH; Aben KK
    Cochrane Database Syst Rev; 2020 Jun; 6(6):CD006590. PubMed ID: 32495338
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Cost-Effectiveness and Quality of Life Analysis of Different Approaches to the Management and Treatment of Localized Prostate Cancer.
    Harat A; Harat M; Martinson M
    Front Oncol; 2020; 10():103. PubMed ID: 32117753
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Systematic review of the cost effectiveness of radiation therapy for prostate cancer from 2003 to 2013.
    Amin NP; Sher DJ; Konski AA
    Appl Health Econ Health Policy; 2014 Aug; 12(4):391-408. PubMed ID: 25022451
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An Age Adjusted Comorbidity Index to Predict Long-Term, Other Cause Mortality in Men with Prostate Cancer.
    Daskivich TJ; Kwan L; Dash A; Saigal C; Litwin MS
    J Urol; 2015 Jul; 194(1):73-8. PubMed ID: 25623745
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-effectiveness of Maintenance Capecitabine and Bevacizumab for Metastatic Colorectal Cancer.
    Sherman SK; Lange JJ; Dahdaleh FS; Rajeev R; Gamblin TC; Polite BN; Turaga KK
    JAMA Oncol; 2019 Feb; 5(2):236-242. PubMed ID: 30489611
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Survival and secondary interventions following treatment for locally-advanced prostate cancer.
    Sussman R; Carvalho FLF; Harbin A; Zheng C; Lynch JH; Stamatakis L; Hwang J; Williams SB; Hu JC; Kowalczyk KJ
    Can J Urol; 2018 Oct; 25(5):9516-9524. PubMed ID: 30281010
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Active surveillance compared with initial treatment for men with low-risk prostate cancer: a decision analysis.
    Hayes JH; Ollendorf DA; Pearson SD; Barry MJ; Kantoff PW; Stewart ST; Bhatnagar V; Sweeney CJ; Stahl JE; McMahon PM
    JAMA; 2010 Dec; 304(21):2373-80. PubMed ID: 21119084
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostate Cancer: An International Multidisciplinary Systematic Review.
    Moris L; Cumberbatch MG; Van den Broeck T; Gandaglia G; Fossati N; Kelly B; Pal R; Briers E; Cornford P; De Santis M; Fanti S; Gillessen S; Grummet JP; Henry AM; Lam TBL; Lardas M; Liew M; Mason MD; Omar MI; Rouvière O; Schoots IG; Tilki D; van den Bergh RCN; van Der Kwast TH; van Der Poel HG; Willemse PM; Yuan CY; Konety B; Dorff T; Jain S; Mottet N; Wiegel T
    Eur Urol; 2020 May; 77(5):614-627. PubMed ID: 32146018
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Active monitoring, radical prostatectomy and radical radiotherapy in PSA-detected clinically localised prostate cancer: the ProtecT three-arm RCT.
    Hamdy FC; Donovan JL; Lane JA; Mason M; Metcalfe C; Holding P; Wade J; Noble S; Garfield K; Young G; Davis M; Peters TJ; Turner EL; Martin RM; Oxley J; Robinson M; Staffurth J; Walsh E; Blazeby J; Bryant R; Bollina P; Catto J; Doble A; Doherty A; Gillatt D; Gnanapragasam V; Hughes O; Kockelbergh R; Kynaston H; Paul A; Paez E; Powell P; Prescott S; Rosario D; Rowe E; Neal D
    Health Technol Assess; 2020 Aug; 24(37):1-176. PubMed ID: 32773013
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The cost-utility of open prostatectomy compared with active surveillance in early localised prostate cancer.
    Koerber F; Waidelich R; Stollenwerk B; Rogowski W
    BMC Health Serv Res; 2014 Apr; 14():163. PubMed ID: 24721557
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.